Docoh
Loading...

28 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
the skin typically on the lower extremities with no currently approved FDA treatments. NL presents more commonly in women than in men and occurs more often
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
approved FDA treatments. NL presents more commonly in women than in men and occurs more often in people with diabetes. Ulceration occurs
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
on the lower extremities with no currently approved FDA treatments. NL presents more commonly in women than in men and occurs more often in people … , the risks associated with giving PCS499 still exists. Given NL patients are mainly women and multiple pathophysiological changes have occurred
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
and the tissue under the skin typically on the lower extremities with no currently approved FDA treatments. NL presents more commonly in women than in men … in women than in men and occurs more often in people with diabetes. Ulceration occurs in approximately 30% of NL patients, which can lead to more severe
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
commonly in women than in men and occurs more often in people with diabetes. Ulceration occurs in approximately 30% of NL patients, which can lead to more … still exists. Given NL patients are mainly women and multiple pathophysiological changes have occurred in their body from the NL, the NL patients could
S-1/A
mxl3v64q4b
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
dq4 gcdklvhb3wyps94
16 Sep 20
IPO registration (amended)
8:00pm
10-Q
r5hn2o5u60
5 Aug 20
Quarterly report
3:32pm
S-1/A
00fbn m66oa
17 Jul 20
IPO registration (amended)
5:25pm
10-Q
zmb5gi
15 May 20
Quarterly report
1:23pm
10-K
jdezd3cppq2b
5 Mar 20
Annual report
7:00pm
S-1
oa87uenrr1b ns
13 Dec 19
IPO registration
5:32pm
10-Q
8gxkoxep1w ce
14 Nov 19
Quarterly report
11:45am
10-Q
s5lmq58w
13 Aug 19
Quarterly report
8:00pm
10-K/A
j3lfd1 e7scp
5 Apr 19
Annual report (amended)
9:40pm
10-K
73d64siqfc387hg
28 Mar 19
Annual report
5:25pm
424B3
3fv5m7bc p8
13 Nov 18
Prospectus supplement
9:39pm
10-Q
y797494 p2
13 Nov 18
Quarterly report
9:37pm
424B3
p097w0c3a68o7o7nf33
9 Nov 18
Prospectus supplement
5:04pm
S-1/A
cvc94t
30 Oct 18
IPO registration (amended)
4:19pm